MacroGenics | MGNX - Sales Revenues


MacroGenics reported $20.8M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Amgen USD 10.1B 1.48B Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
Biogen USD 2.74B 490M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Daiichi Sankyo JPY 574.74B 12.26B Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Genmab DKK 1.16B 259M Jun/2026
Geron USD 57.48M 5.64M Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
J&J USD 25.31B 1.21B Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Merck USD 16.6B 310M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Xencor USD 51.22M 46.71M Jun/2026